Literature DB >> 2787386

Self recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens.

R C Duke1.   

Abstract

Activated CTL can kill any cell to which they bind or by which they are bound. This observation has been used to determine whether alloreactive CTL can recognize cells bearing self-MHC. When activated by their specific targets, 19 CTL clones of 4 different specificities and origins killed bystander targets bearing syngeneic but not third-party MHC antigens. Using target cells derived from MHC-recombinant animals, syngeneic bystander killing was shown to be restricted to a single self MHC-encoded molecule. These results provide the first clear demonstration that T cells, or more precisely CTL, are capable of self recognition in the absence of their specific antigen. Our findings support the model that T cell repertoire selection occurs as a result of positive selection during maturation in the thymus of precursor cells whose antigen receptors have low but real affinity for self-MHC.

Mesh:

Substances:

Year:  1989        PMID: 2787386      PMCID: PMC2189386          DOI: 10.1084/jem.170.1.59

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  Anti-T cell receptor antibodies fail to inhibit specific lysis by CTL clones but activate lytic activity for irrelevant targets.

Authors:  T J Henkel; V L Braciale; T J Braciale
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

Review 2.  T-cell antigen receptor genes and T-cell recognition.

Authors:  M M Davis; P J Bjorkman
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

3.  Cloned cytotoxic T lymphocytes as target cells. II. Polarity of lysis revisited.

Authors:  K Gorman; C C Liu; A Blakely; J D Young; B E Torbett; W R Clark
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

4.  The effect of thymus environment on T cell development and tolerance.

Authors:  P Marrack; D Lo; R Brinster; R Palmiter; L Burkly; R H Flavell; J Kappler
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

5.  Structure of the human class I histocompatibility antigen, HLA-A2.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

6.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes.

Authors:  P Kisielow; H Blüthmann; U D Staerz; M Steinmetz; H von Boehmer
Journal:  Nature       Date:  1988-06-23       Impact factor: 49.962

7.  Lysis of bystander target cells after triggering of human cytotoxic T lymphocytes.

Authors:  B Fleischer
Journal:  Eur J Immunol       Date:  1986-08       Impact factor: 5.532

8.  Requirements for triggering of lysis by cytolytic T lymphocyte clones.

Authors:  D W Lancki; A Weiss; F W Fitch
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

9.  A calcium- and perforin-independent pathway of killing mediated by murine cytolytic lymphocytes.

Authors:  J D Young; W R Clark; C C Liu; Z A Cohn
Journal:  J Exp Med       Date:  1987-12-01       Impact factor: 14.307

10.  Resistance of cloned cytotoxic T lymphocytes to cell-mediated cytotoxicity.

Authors:  A Blakely; K Gorman; H Ostergaard; K Svoboda; C C Liu; J D Young; W R Clark
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  16 in total

Review 1.  A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-06-21       Impact factor: 3.584

2.  Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses.

Authors:  Aurelie Wiedemann; David Depoil; Mustapha Faroudi; Salvatore Valitutti
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

Review 3.  Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

Authors:  Robert S Fujinami; Matthias G von Herrath; Urs Christen; J Lindsay Whitton
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 4.  Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity.

Authors:  Maurizio Rinaldi; Roberto Perricone; Miri Blank; Carlo Perricone; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 5.  Protection against or triggering of Type 1 diabetes? Different roles for viral infections.

Authors:  Tobias Boettler; Matthias von Herrath
Journal:  Expert Rev Clin Immunol       Date:  2011-01       Impact factor: 4.473

6.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

7.  Recognition of the major histocompatibility complex restriction element modulates CD8(+) T cell specificity and compensates for loss of T cell receptor contacts with the specific peptide.

Authors:  J K Sandberg; K Kärre; R Glas
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307

8.  Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.

Authors:  B Leshem; E Kedar
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

9.  Fas ligand-mediated lysis of self bystander targets by human papillomavirus-specific CD8+ cytotoxic T lymphocytes.

Authors:  M J Smyth; E Krasovskis; R W Johnstone
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones. A novel potentially immunoregulatory T-T cell interaction in man.

Authors:  T H Ottenhoff; T Mutis
Journal:  J Exp Med       Date:  1990-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.